About VerImmune
VerImmune is a company based in Baltimore (United States) founded in 2019 by John Troyer and Joshua Wang.. VerImmune has raised $10.13 million across 4 funding rounds from investors including Beiley Biofund, Proxima Ventures and Mana Ventures. VerImmune offers products and services including Anti-Tumor Immune Redirection (AIR). VerImmune operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Baltimore, United States
- Founders John Troyer, Joshua Wang
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Verimmune, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10.13 M (USD)
in 4 rounds
-
Latest Funding Round
$4.5 M (USD), Seed
Sep 23, 2024
-
Investors
Beiley Biofund
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VerImmune
VerImmune offers a comprehensive portfolio of products and services, including Anti-Tumor Immune Redirection (AIR). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy redirects immune memory to target and destroy cancer cells.
Funding Insights of VerImmune
VerImmune has successfully raised a total of $10.13M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $4.5 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $4.5M
-
First Round
First Round
(01 May 2020)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Seed - VerImmune | Valuation | Beiley Biofund | |
| Sep, 2023 | Amount | Seed - VerImmune | Valuation | Proxima Ventures | |
| Jul, 2022 | Amount | Seed - VerImmune | Valuation | SeedFolio |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in VerImmune
VerImmune has secured backing from 9 investors, including venture fund and angel investors. Prominent investors backing the company include Beiley Biofund, Proxima Ventures and Mana Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in biotechnology startups is facilitated by Beiley Biofund.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments in early-stage tech firms and consumer brands are made.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by VerImmune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - VerImmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Verimmune Comparisons
Competitors of VerImmune
VerImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Verimmune
Frequently Asked Questions about VerImmune
When was VerImmune founded?
VerImmune was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is VerImmune located?
VerImmune is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Who is the current CEO of VerImmune?
Joshua Wang is the current CEO of VerImmune. They have also founded this company.
Is VerImmune a funded company?
VerImmune is a funded company, having raised a total of $10.13M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.5M, raised on May 01, 2020.
What does VerImmune do?
VerImmune was founded in 2019 in Baltimore, United States, as a biotechnology firm focused on oncology. Vaccines for cancer treatment are developed through Anti-tumor Immune Redirection (AIR) technology, by which pre-existing immune memory from childhood vaccines or infections is redirected against tumors. A papillomavirus nanoparticle conjugated with viral antigens has been created to support this approach. Operations center on advancing these therapeutic innovations.
Who are the top competitors of VerImmune?
VerImmune's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does VerImmune offer?
VerImmune offers Anti-Tumor Immune Redirection (AIR).
Who are VerImmune's investors?
VerImmune has 9 investors. Key investors include Beiley Biofund, Proxima Ventures, Mana Ventures, Gaingels, and John Ballantyne.